Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available-for-Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2014 were as follows (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
U.S. government and government agency obligations	$	7,397	$	12	$	(15	)	$	7,394
Mortgage-backed securities		5,576		43		(74	)		5,545
Municipal bonds		1,173		5		(3	)		1,175
Asset-backed securities		2,370		3		(4	)		2,369
Corporate bonds		1,829		6		(5	)		1,830
Equity securities		2		1,548		—			1,550
Total	$	18,347	$	1,617	$	(101	)	$	19,863

Sales of Available-for-Sale Securities

The following table summarizes sales of available-for-sale securities for the years ended September 30, 2015, 2014 and 2013 (in thousands):

	2015			2014			2013
Proceeds from sales	$	22,199		$	162,673		$	44,853
Gross realized gains	$	548		$	134		$	179
Gross realized losses	$	(73	)	$	(1	)	$	(43	)

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2015		2014
Raw materials	$	1,264	$	1,056
Finished products		1,715		1,761
Total	$	2,979	$	2,817

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2015			2014
	(In years)
Land	N/A	$	4,359		$	4,359
Laboratory fixtures and equipment	3 to 10		12,941			12,858
Buildings and improvements	3 to 20		16,444			16,114
Office furniture and equipment	3 to 10		3,473			3,060
Construction-in-progress			1,168			1,158
Less accumulated depreciation			(25,417	)		(24,416	)
Property and equipment, net		$	12,968		$	13,133

Schedule of Other Assets Consist Principally of Strategic Investments

Other assets consisted principally of strategic investments as of September 30 as follows (in thousands):

	2015		2014
CeloNova BioSciences, Inc.	$	—	$	1,500
ViaCyte, Inc.		479		479
Other assets, net	$	479	$	1,979

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2015
	Weighted Average Original Life(Years)		GrossCarrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	5,132	$	(4,363	)	$	769
Core technology		8.0		530		(530	)		0
Non-compete		5.0		230		(12	)		218
Patents and other	16.8			2,321		(1,128	)		1,193
Subtotal				8,213		(6,033	)		2,180
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,793	$	(6,033	)	$	2,760

	2014
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	4,857	$	(3,813	)	$	1,044
Core technology		8.0		530		(475	)		55
Patents and other		16.8		2,256		(989	)		1,267
Subtotal				7,643		(5,277	)		2,366
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,223	$	(5,277	)	$	2,946

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2015, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2016	$	690
2017		279
2018		233
2019		233
2020	221

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share (in thousands):

	2015		2014		2013
Net income from continuing operations available to common    shareholders	$	11,947	$	12,207	$	14,579
Basic weighted average shares outstanding		13,029		13,632		14,464
Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units and performance    shares		260		244		267
Diluted weighted average shares outstanding		13,289		13,876		14,731